What Is PMOS and Why Was PCOS Renamed?

PMOS is the new name for PCOS, adopted in May 2026. It affects 1 in 8 women, and the name now reflects its hormonal and metabolic effects, not cysts.

PMOS, or polyendocrine metabolic ovarian syndrome, is the new name for polycystic ovary syndrome (PCOS), adopted in May 2026 after a global consensus published in The Lancet. It was renamed because most people with the condition do not have abnormal ovarian cysts, and the old name hid its hormonal and metabolic effects.

This article draws on the 2026 Lancet consensus paper, the Monash Centre for Health Research and Implementation terminology update, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) statement, the WHO fact sheet, NHS guidance, and a 2016 meta-analysis in Human Reproduction, current as of October 2026.

Why Was PCOS Renamed to PMOS?

PCOS was renamed PMOS because the old name was inaccurate and focused attention on the ovaries alone. The Lancet consensus paper states that "the term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features". The authors link the old name to delayed diagnosis, fragmented care, and stigma.

The new name came from a process involving 56 academic, clinical, and patient organisations. Global surveys drew responses from 14,360 people with the condition and health professionals across every world region. The Monash terminology update says the work took 14 years and notes that pathological cysts are not a feature of the condition. RANZCOG, which welcomed the change in May 2026, adds that the old name led some patients to fear they needed surgery for cysts. The aim is a name that matches what the condition actually does.

What Does Polyendocrine Metabolic Ovarian Syndrome Mean?

Polyendocrine metabolic ovarian syndrome means a condition that affects several hormone systems, the body's metabolism, and the ovaries at once. Polyendocrine covers hormones such as androgens (male-type hormones like testosterone), luteinising hormone (LH), and insulin. Metabolic points to insulin resistance, and ovarian to irregular ovulation, which disrupts the hormone sequence described in the guide to the four cycle phases.

The metabolic part is well documented. A 2016 meta-analysis of 28 insulin clamp studies in Human Reproduction found insulin sensitivity was 27% lower in women with the condition, independent of body weight. That is why blood sugar matters as much as periods, as covered in the guide to whether sugar affects hormones. How PMOS fits among other hormonal causes is set out in the guide to what causes hormonal imbalance in women.

Solu is a women's wellness app that maps cycle-phase-aware guidance across movement, nutrition, sleep, and energy, built for women tracking hormonal, cycle, and premenstrual symptoms. Logging symptoms, energy, and mood in Solu builds trends across months, so irregular gaps between periods stand out clearly.

What Changes for Women Already Diagnosed With PCOS?

For women already diagnosed with PCOS, very little changes in practice: the diagnosis stays valid, and treatment plans do not change automatically. The Monash update confirms the international guideline's recommendations and content stay the same. Only the name and the emphasis on metabolic and hormonal health have shifted.

What changes and what stays, based on the Lancet, Monash, and RANZCOG sources:

Name: PMOS is the new term, written as PMOS/PCOS in the international guideline from May 2026.
Diagnosis and treatment: the guideline's criteria and recommendations are unchanged.
Timeline: both names co-exist during a 3-year transition, and the 2028 guideline will use PMOS as standard.
Care focus: long-term risks such as type 2 diabetes and high blood pressure gain the same weight as periods and fertility.

Weighed together, these sources describe a change of label and emphasis, not a new disease or new treatment rules. As of 2026, the NHS page, reviewed in June 2026, already uses the PMOS name.

How Is PMOS Managed Day to Day?

PMOS has no cure, but its symptoms and long-term risks can be managed with lifestyle changes and, where needed, medicines. The NHS recommends a healthy balanced diet, regular exercise, and weight loss for those who are overweight. Treatments include the combined pill for irregular periods, metformin, and clomifene for fertility.

Management matters because the condition is common and often missed. The WHO fact sheet, updated in January 2026, estimates 10 to 13% of women are affected and up to 70% are undiagnosed. It lists risks including type 2 diabetes, high blood pressure, sleep apnoea, anxiety, and depression. Solu offers phase-based nutrition guidance, such as iron-rich foods during the menstrual phase, which can sit alongside a dietitian's blood sugar plan. Food choices for women trying to conceive are covered in the guide to what to eat to get pregnant faster, and fitting in regular activity is covered in the guide to the best time of day to work out.

When Should You See a Doctor About PMOS Symptoms?

See a GP if periods regularly come less than 21 days or more than 35 days apart, the normal range given by the NHS. Also book a visit after 3 missed periods in a row with a negative pregnancy test. New acne, excess facial hair, or hair thinning are further reasons to get checked.

At a GP appointment, a written log showing 6 periods in the past 12 months gives a clearer starting point than a vague note about irregular periods. Seek an urgent appointment for extreme thirst, peeing much more often, or unexplained weight loss, which can signal high blood sugar. Low mood or anxiety that affects daily life also deserves prompt support.

Key Takeaways

PCOS was renamed polyendocrine metabolic ovarian syndrome (PMOS) in May 2026, following a consensus published in The Lancet.
The condition affects about 1 in 8 women, and the WHO estimates up to 70% are undiagnosed.
Existing PCOS diagnoses stay valid, and the guideline's recommendations are unchanged during a 3-year transition.
Insulin sensitivity is about 27% lower in women with the condition, independent of body weight.